The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
Open accessAbstract
Among the earliest and most important stages during tumorigenesis is the activation of the angiogenic process, an event that is termed the “switch to the angiogenic phenotype.” We have developed an in vivo system that can reliably recapitulate the stages in tumor development that represent this transition. Using this model, we have harvested and studied tumor nodules that can be distinguished from each other on the basis of their degree of vascularization. Angiogenic tumor nodules were characterized by the presence of capillary vessels as determined by factor VIII immunohistochemistry, and both angiogenic and proteolytic activities in vitro . In contrast, preangiogenic nodules were devoid of microvessels and showed little angiogenic or proteolytic activity in vitro . Addition of a specific metalloproteinase inhibitor resulted in the abrogation of both angiogenic and proteolytic activities of the angiogenic nodules in vitro . Comparative substrate gel electrophoresis detected the presence of a prominent matrix metalloproteinase (MMP-2) in the angiogenic nodules when compared with the preangiogenic ones. Suppression of MMP-2 activity by antisense oligonucleotides in the vascular nodules resulted in the loss of angiogenic potential both in vitro and in vivo in the chick chorioallantoic membrane assay. Moreover, this suppression of MMP-2 activity in angiogenic nodules inhibited tumor growth in vivo by approximately 70%. These results strongly implicate the activity of MMP-2 as a requirement for the switch to the angiogenic phenotype and validate this model as a reliable and reproducible tool by which to study other cellular and biochemical factors involved in the acquisition of the angiogenic phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Nagase, H., & Woessner, J. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21491 · Cited by 3,912
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Vu, T. H., Shipley, J. M., Bergers, G., Berger, J. E., Helms, J. A., Hanahan, D., Shapiro, S. D., Senior, R. M., & Werb, Z. (1998) · Cell · doi:10.1016/s0092-8674(00)81169-1 · Cited by 1,750
Ausprunk, D. H., & Folkman, J. (1977) · Microvascular Research · doi:10.1016/0026-2862(77)90141-8 · Cited by 1,281
Cited by
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
How Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
“Although MMP2 does not appear to influence angiogenesis in the above model, its downregulation by targeted gene disruption and antisense methods does suppress tumorinduced angiogenesis in other models (T Itoh et al. 1998, Fang et al. 2000).”
BackgroundMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Matrix metalloproteinases and tumor metastasis
Deryugina, E. I., & Quigley, J. P. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7886-9 · Cited by 1,960
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Extracellular matrix remodelling: the role of matrix metalloproteinases
Stamenkovic, I. (2003) · The Journal of Pathology · doi:10.1002/path.1400 · Cited by 1,140
Matrix metalloproteinases and angiogenesis
Rundhaug, J. E. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00355.x · Cited by 960
Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer
Roy, R., Yang, J., & Moses, M. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5556 · Cited by 854
Self-citationMechanobiology and diseases of mechanotransduction
Ingber, D. (2003) · Annals of Medicine · doi:10.1080/07853890310016333 · Cited by 843
Role of the Matrix Metalloproteinase and Plasminogen Activator–Plasmin Systems in Angiogenesis
Pepper, M. S. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0701.093685 · Cited by 777
In vivo molecular target assessment of matrix metalloproteinase inhibition
Bremer, C., Tung, C.-H., & Weissleder, R. (2001) · Nature Medicine · doi:10.1038/89126 · Cited by 726
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
Zucker, S., Cao, J., & Chen, W.-T. (2000) · Oncogene · doi:10.1038/sj.onc.1204097 · Cited by 550
Xie, T.-X., Wei, D., Liu, M., Gao, A. C., Ali-Osman, F., Sawaya, R., & Huang, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207383 · Cited by 550
Complex roles of tissue inhibitors of metalloproteinases in cancer
Jiang, Y., Goldberg, I. D., & Shi, Y. E. (2002) · Oncogene · doi:10.1038/sj.onc.1205291 · Cited by 507
Identification of Novel, Functional Genetic Variants in the Human Matrix Metalloproteinase-2 Gene
Price, S. J., Greaves, D. R., & Watkins, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010242200 · Cited by 406
Tang, Y., Nakada, M. T., Kesavan, P., McCabe, F., Millar, H., Rafferty, P., Bugelski, P., & Yan, L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3605 · Cited by 337
Self-citationDas, S., Singh, S., Dowding, J. M., Oommen, S., Kumar, A., Sayle, T. X. T., Saraf, S., Patra, C. R., Vlahakis, N. E., Sayle, D. C., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.07.019 · Cited by 309
Metalloproteinases and their inhibitors in tumor angiogenesis
Handsley, M. M., & Edwards, D. R. (2005) · International Journal of Cancer · doi:10.1002/ijc.20945 · Cited by 307
Human endothelial gelatinases and angiogenesis
Nguyen, M. (2001) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00007-3 · Cited by 300
Matrix metalloproteinases in tumorigenesis: an evolving paradigm
Hua, H., Li, M., Luo, T., Yin, Y., & Jiang, Y. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0763-x · Cited by 300
Inhibition of tumor angiogenesis by cannabinoids
Blázquez, C., Casanova, M. L., Planas, A., Gómez del Pulgar, T., Villanueva, C., Fernández‐Aceñero, M. J., Aragonés, J., Huffman, J. W., Jorcano, J. L., & Guzmán, M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0795fje · Cited by 292
Optical-based molecular imaging: contrast agents and potential medical applications
Bremer, C., Ntziachristos, V., & Weissleder, R. (2003) · European Radiology · doi:10.1007/s00330-002-1610-0 · Cited by 286
Fernández, C. A., Yan, L., Louis, G., Yang, J., Kutok, J. L., & Moses, M. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2391 · Cited by 283
Self-citationOptical imaging in drug discovery and diagnostic applications
LICHA, K., & OLBRICH, C. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.01.021 · Cited by 263
Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis
Foda, H. D., & Zucker, S. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01752-4 · Cited by 262
Sounni, N. E., Devy, L., Hajitou, A., Frankenne, F., Munaut, C., Gilles, C., Deroanne, C., Thompson, E. W., Foidart, J. M., & Noel, A. (2002) · The FASEB Journal · doi:10.1096/fj.01-0790com · Cited by 260
Robinet, A., Fahem, A., Cauchard, J.-H., Huet, E., Vincent, L., Lorimier, S., Antonicelli, F., Soria, C., Crepin, M., Hornebeck, W., et al. (2005) · Journal of Cell Science · doi:10.1242/jcs.01613 · Cited by 259
Tang, Y., Kesavan, P., Nakada, M. T., & Yan, L. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.73.2.2 · Cited by 256
Self-citationOptical Imaging of Matrix Metalloproteinase–2 Activity in Tumors: Feasibility Study in a Mouse Model
Bremer, C., Bredow, S., Mahmood, U., Weissleder, R., & Tung, C.-H. (2001) · Radiology · doi:10.1148/radiol.2212010368 · Cited by 255
Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2
Hu, B., Guo, P., Fang, Q., Tao, H.-Q., Wang, D., Nagane, M., Su Huang, H.-J., Gunji, Y., Nishikawa, R., Alitalo, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533394100 · Cited by 164
Metadata
- Authors
- Fang, J., Shing, Y., Wiederschain, D., Yan, L., Butterfield, C., Jackson, G., Harper, J., Tamvakopoulos, G., & Moses, M. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-04-11
- Volume
- 97
- Issue
- 8
- Pages
- 3884-3889
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2083535354
- Cited by
- 393
- References
- 43
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.